Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business corporate formation

Psyence BioMed Forms Texas Ibogaine Unit

Analysis based on 8 articles · First reported Sep 14, 2026 · Last updated Sep 14, 2026

Sentiment
5
Attention
2
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The announcement is a small-cap corporate development for Psyence BioMed and is unlikely to move broad markets, though it may draw speculative interest in psychedelic and neuroplastogen biotech names. The stock reaction is likely modest and company-specific, with execution and licensing risk limiting any sustained re-rating.

biotechnology pharmaceuticals

Psyence Biomedical Ltd. (Nasdaq: PBM) announced on September 14, 2026 the formation of Texas Ibogaine Research Corporation (TIRC), a Texas-based company established to coordinate the Company's U.S. ibogaine development activities, including pharmaceutical-grade supply, regulatory engagement and potential clinical development. TIRC is intended to serve as Psyence BioMed's dedicated U.S. vehicle for the regulated development of ibogaine. Subject to completion of definitive licensing arrangements, TIRC is positioned to hold U.S. rights to pharmaceutical-grade ibogaine developed by PsyLabs, a neuroplastogen active pharmaceutical ingredient development company in which Psyence BioMed holds an ownership interest. The Company intends for TIRC to coordinate applicable rights, manufacturing arrangements, regulatory documentation and any future investigational new drug application within a single U.S. entity financed by Psyence BioMed, and to serve as counterparty of record in engagements with federal agencies, state programs and potential clinical partners in the United States. Jody Aufrichtig, Chief Executive Officer of Psyence BioMed, will also serve as CEO of TIRC, while Dr. John Thornton has been appointed project lead. Psyence BioMed expects to provide technical, legal, administrative and financial support through existing internal resources, with corporate oversight from Chief Financial Officer Warwick Corden-Lloyd and the in-house legal function. The formation follows U.S. policy and research developments involving neuroplastogens, including an Executive Order signed on April 18, 2026 directing federal agencies to accelerate relevant research, coordinated federal implementation announced in July 2026, and the provision of the University of Miami's original 1994 ibogaine investigational new drug application to the U.S. Department of Health and Human Services. Next steps include completing definitive licensing arrangements, advancing regulatory engagement and developing manufacturing and clinical plans, all subject to applicable laws and regulatory requirements.

stock
Psyence BioMed is the parent forming TIRC and financing its U.S. ibogaine development activities. The move gives it a dedicated U.S. vehicle for licensing, regulatory and clinical work, a modest positive for its pipeline narrative but subject to execution risk.
Importance 100.0 Sentiment 15.0
priv
TIRC is the newly formed Texas subsidiary intended to hold U.S. rights to pharmaceutical-grade ibogaine and coordinate supply, manufacturing, regulatory and clinical activities. Its value depends on completing definitive licensing arrangements with PsyLabs.
Importance 95.0 Sentiment 10.0
priv
PsyLabs is the neuroplastogen API developer whose pharmaceutical-grade ibogaine would be licensed to TIRC. The arrangement could expand PsyLabs' U.S. distribution and regulatory footprint if definitive licensing is completed.
Importance 70.0 Sentiment 5.0
per
Aufrichtig is CEO of both Psyence BioMed and TIRC, giving him direct oversight of the U.S. ibogaine strategy. His dual role concentrates leadership responsibility for the new entity.
Importance 45.0 Sentiment 5.0
cnt
The United States is the jurisdiction where TIRC will pursue regulated ibogaine development, following federal policy moves including an April 2026 Executive Order and July 2026 implementation.
Importance 40.0 Sentiment 0.0
per
Thorne has been appointed project lead for TIRC, responsible for coordinating the material, regulatory documentation, manufacturing pathway and clinical development plan.
Importance 35.0 Sentiment 5.0
govactor
HHS received the University of Miami's original 1994 ibogaine investigational new drug application, part of the federal policy backdrop that TIRC intends to engage with.
Importance 25.0 Sentiment 0.0
per
Corden-Lloyd, Psyence BioMed's CFO, provides corporate oversight of TIRC's financing and support through existing internal resources.
Importance 20.0 Sentiment 0.0
exch
Nasdaq is the listing venue for Psyence BioMed (PBM); the company notes continued listing standards as a risk factor in its forward-looking statements.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.